Community-Based CAR-T: Examining Outcomes and Site Readiness with Real-World Data

Chimeric Antigen Receptor T cell (CAR-T cell) therapy has transformed hematology-oncology and is generating increasing interest in other therapeutic areas, including solid tumors, rheumatology, and autoimmune diseases. As sponsors look beyond traditional academic medical centers, real-world evidence can help clarify what responsible expansion into community settings requires. 

This webinar will examine real-world data comparing safety and clinical outcomes for CAR-T therapies delivered at Foundation for the Accreditation of Cellular Therapy (FACT)-accredited and non-FACT-accredited sites. Speakers will discuss what these findings may mean for site readiness, accreditation, oversight, and implementation — and how sponsors and sites can evaluate opportunities to expand CAR-T research and care while maintaining patient safety and trial quality. 
 

Learning Objectives 

After attending this webinar, participants will be able to: 

• Describe historical challenges and barriers to bringing CAR-T research and clinical care to community sites. 

• Explain the advantages and limitations of site accreditation for cellular therapy, including how accreditation may factor into sponsor and site readiness decisions. 

• Interpret real-world safety and clinical outcome data comparing accredited and non-accredited CAR-T sites. 

• Assess how these findings may inform clinical trial site selection, oversight planning, and responsible implementation of CAR-T therapy in community settings.